HRV Pharma, a global virtual pharmaceutical company, has launched RIKO™, an AI-native pharmaceutical operating system developed from the company’s operational experience across the pharmaceutical value chain. Built on over seven years of institutional knowledge and more than 2.4 million proprietary reasoning events, the platform is designed to support faster and more informed decision-making across sales, regulatory affairs, quality and supply chain operations.
Developed using HRV’s operating history across a network of more than 50 FDA and EU-GMP-certified manufacturing partners and customers in 55 countries, RIKO™ continuously learns from real-world pharmaceutical decisions. The platform evaluates chemistry risk, nitrosamine potential, supplier performance, regulatory history, manufacturing capability and commercial alignment before sourcing or licensing decisions are finalized.
The company said RIKO™ currently delivers 94% predictive accuracy in identifying potential nitrosamine-related risks during early assessments. It has also reduced supplier qualification timelines by 85%, while maintaining human oversight, and screens all inbound commercial inquiries with opportunity scoring and supplier matching in under two seconds.
“We didn’t begin by asking how AI could fit into our business. We started by asking why the same preventable problems continue to surface years after critical manufacturing and sourcing decisions have already been made. That question became the foundation of RIKO,” said Hari Kiran Chereddi, Founder, Managing Director and Chief Executive Officer, HRV Pharma. “Large language models have become increasingly accessible. Manufacturing capacity can be expanded. Technology can be replicated. What takes years to build is institutional intelligence—the accumulated understanding of how pharmaceutical decisions actually unfold across chemistry, regulation, quality, supply and commercialization. We believe that will define the next generation of industry leaders.”
Commenting on the launch, Sowjanya Varma, Chief Information Officer, HRV Pharma, said, “We didn’t build RIKO simply to automate work. We built it to compound judgment. Our objective has always been to identify risk beforehand, not after a quality failure, regulatory finding or product recall. Every regulatory interaction, supplier assessment, deviation, technical evaluation and commercial outcome strengthens the system’s ability to support better decisions.”
HRV Pharma said RIKO™ represents a purpose-built operational intelligence platform aimed at helping pharmaceutical companies improve compliance, strengthen risk management and enhance decision-making across the value chain.
